Founded in 2011, NovellusDX has brought together a team of skilled individuals from several fields, including synthetic biology, functional genomics, bioinformatics, engineering, algorithm development, clinical laboratory and healthcare commercialization. Together, they lead the company’s mission to deliver evidence-based clinical insights and enable oncology professionals to treat every cancer and each patient with the precise treatment and to support pharmaceutical companies with their drugs life cycle.
Board of Directors
Prof. Aaron Ciechanover, PhD, MD
Nobel Prize laureate, 2004 (“the discovery of ubiquitin-mediated protein degradation“). Head of Tumor and Vascular Biology Research Center, the Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology
Prof. Yoram Palti, PhD, MD
Founder of NovoCure. Professor emeritus of physiology & biophysics at the Technion – Israel Institute of Technology
Prof. Amit Meller, PhD
Professor of Biomedical Engineering, Technion – Israel Institute of Technology
Vered Behar, PhD, MBA
Chief Scientific Officer, Vidac Pharma. Dr. Behar served in executive positions at Dynamix Pharmaceuticals and Quantomix, as well as a technology scout for Third Rock Ventures. Dr. Behar also served as a research scientist at Pfizer in Cambridge, MA. Dr. Behar earned her PhD in Molecular Pharmacology from the Division of Medical Sciences at Harvard University where she was awarded the prestigious Ryan Fellowship.
Prof. Nir Peled, MD, PhD, FCCP, Head of Medical Advisory Board
Thoracic Cancer Unit, Davidoff Cancer Center, RMC, Petach Tiqwa, Israel. Faculty member at the Sackler Faculty of Medicine, Tel Aviv University, Israel
Yishai Ofran, MD, Medical Advisory Board
Senior Hematologist at the Department of Hematology and Bone Marrow Transplantation at Rambam Health Care Campus in Haifa, Israel. Director of Hematological bio-bank and a Research Fellow at Dana-Farber Cancer Institute.
Mr. Gil-Ad brings more than 25 years of experience in management of large R&D projects. Prior to founding NovellusDx, Haim Gil-Ad was the CEO of Optigo Systems Ltd., a vertically integrated high-tech company developing technology-oriented products and a leader in electro-optical R&D that was acquired by the Elta Co. of Israel Aerospace Industries. Prior to joining Optigo, Mr. Gil-Ad pursued an extensive career with the Israeli Ministry of Defense (IMOD) as head of major international R&D and full-scale development programs. Mr. Gil-Ad earned a B.Sc. in Engineering from Tel-Aviv University and an MBA from Ben-Gurion University. He has twice been awarded the Israel National Quality Award.
MICHAEL VIDNE, PhD
Chief Commercial Officer
Dr. Vidne joined NovellusDx 2013 bringing with him experience in both management and mathematical analysis. Prior to joining NovellusDx, Dr. Vidne was a consultant with McKinsey & Co. in the US West Coast Office serving mainly the high-tech and semiconductor industries. Michael received his Ph.D. in Applied Mathematics from Columbia University in 2011, where he employed machine learning and statistical methods to research the mammalian visual system and neuron populations.
GABI TARCIC, PhD
Dr. Tarcic joined NovellusDx in 2012, bringing extensive experience in cancer cell biology and signal transduction. He was a Post-Doctoral fellow at the Weizmann Institute of Science, where he also earned a Ph.D. in the lab of Prof. Yosef Yarden studying Modular regulation of signal transduction networks. Dr. Tarcic published his research in leading peer-reviewed scientific journals such as Current Biology, FASEB Journal and Nature Genetics and co-edited a book titled Vesicle Trafficking in Cancer, which was published by Springer Press. Dr. Tarcic received his B.Sc. with honors from the Hebrew University in Jerusalem.
ZOHAR BARBASH, PhD
Director, Assay Development
Dr. Barbash joined NovellusDx in 2014, bringing expertise in molecular and cellular biology with extensive experience in cancer biology. Prior to joining NovellusDx, Dr. Barbash was a Postdoctoral Fellow at the American National Cancer Institute at NIH, Bethesda, MD. in the lab of Dr. Dinah Singer, where she specialized in mice in vivo models for cancer and obesity, transcription and epigenetic mechanisms of diseases. Dr. Barbash holds an, M.sc in Human Genetics and PhD in molecular biology from the Tel Aviv University.
ODED ECELHEIT, PhD
Head of Clinical Lab
Dr. Edelheit Joined NovellusDx in 2015 bringing expertise in molecular and cellular biology, with extensive experience in basic and applied research. Prior to joining NovellusDx, Dr. Edelheit was the CEO and owner of Progen, a protein and gene engineering company, specialized in molecular biology projects tailored to specific customer needs. His company served a variety of academic research groups in academia as well as many biotechnology companies. Dr. Edelheit began his academic training in the field of Bioengineering, and later received an M.Sc and Ph.D in Human Genetics from the Tel Aviv University, Sackler School of Medicine.
Director, Quality Management
Ms. Gaziel has over 20 years’ experience in the field of pharmaceutical and biotech quality assurance and regulatory compliance. Her areas of expertise include an excellent knowledge of quality management systems regulations such as ISO 13485:2016, ISO 9001:2015, IVD Directive 98/79 EC, CLIA, and the FDA’s Quality Systems Regulations 21 CFR. Prior to joining NovellusDX, Ms. Gaziel ran the Quality Management department at Syntezza Molecular Detection, an In-Vitro Diagnostic company which developed and manufactured molecular diagnostic tests for the rapid detection of infectious diseases. Previous to that she spent many years supervising the quality of the production and warehouse departments of Dexcel Pharma Ltd., one of the top Israeli pharmaceutical companies.
Ori Zelichov, MD
Director, Medical Affairs
Dr. Zelichov received his M.D degree from Ben Gurion University and completed his internship at Tel Aviv Medical Center. Prior to joining NovellusDx, Dr. Zelichov was the co-founder of Boomerang Therapeutics, a startup that developed a cancer gene therapy, winning the international iGEM competition in synthetic biology and selected as the best Israeli startup at the Global Innovation Awards. Dr. Zelichov worked as a cancer researcher at the Israeli National Institute for Biotechnology, where he studied cancer biomarkers and published his research in a peer-reviewed journal. Dr. Zelichov served for 4 years at the Israeli Intelligence unit 8200 as a graduate of the elite ‘Haman Talpiot’ leadership project.
DR. CHARLES WOLER, MD
President of the board
Charles Woler has spent the last 30 years in the healthcare industry, both in large multinational pharmaceutical companies, SMEs and also in smaller, earlier stage Biotech companies. His positions have included CEO of Roche France, CEO of SmithKline Beecham’s European pharmaceutical business (London), CEO of Cadus Pharmaceuticals (US), CEO of Neuro3d & Endotis Pharma (France), and recently Biomnis (France). He holds non-executive chairman and directorship positions in different European countries, the US and Israel.
GILAD (Gili) MORAN
Executive Director of the Board
Mr. Moran brings with him more than 35 years of experience in Management and R&D. Prior to serving on the board of NovellusDx, Mr. Moran was the CEO of Mediviz Systems Inc., a medical IT company in Los Angeles with a daughter company in Israel, involved in resource management products for hospitals. Prior to joining Mediviz, Mr. Moran was the CEO of TICI Software Systems, specializing in contract development of real-time SW. The company was sold to Taldor Systems Ltd. Mr. Moran received the Israel Defense Award in 1992 and Intelligence Forces Award for Creative Thinking in 1982. Mr. Moran earned a B.Sc. Cum Laude in Electrical Engineering from Ben-Gurion University in Beer-Sheba and an Executive MBA from Tel-Aviv University. As of yet, Mr. Moran has had five exits. Gili is also in charge of process oversight at NovellusDx.
DR. HEINER DREISMANN
Dr. Dreismann is a seasoned executive with more than 30 years of experience in the healthcare industry and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique, one of the most ubiquitous technologies in molecular biology and genetics research today. He had a successful career with the Roche Group from 1985 to 2006 where he held several senior positions, including President and CEO of Roche Molecular Systems, Head of Global Business Development of Roche Diagnostics, and membership in Roche’s Global Diagnostic Executive Committee. Dr. Dreismann currently serves on the boards of several public and private health care companies.
Ran is a managing partner and co-founder of The Pontifax Group. The fund is running more than 45 portfolio companies all around the globe. Prior to joining Pontifax, he was a partner at Israel’s largest business intelligence and strategic consulting firm. Ran’s work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. Ran serves as a board member on many of Pontifax’s portfolio companies, including Keros (as chairman), Kite pharma (public co.) UroGen pharma, cCAM Biotherapeutics (bought by Merck), Eloxx Pharmaceuticals, Nutrinia Ltd, Novellus Ltd, Quiet Therapeutics and other bio-pharma companies. He also chaired Ocon Medical, NasVax and ran Biomedix Ltd and Spearhead Ltd in the past.
Erez Chimovits is a Senior Managing Director at OrbiMed. Erez has 14 years of operational experience, including 10 years of senior managerial experience in public companies. Prior to joining OrbiMed Erez was the CEO of NasVax (TASE:NSVX). NasVax acquired Protea and struck agreements with GlaxoSmithKline and Novartis. Previously, Erez spent more than seven years with Compugen (Nasdaq:CGEN), as President, Compugen USA Inc. and Executive V.P., Commercial Operations. At Compugen, he had P&L responsibility for more than 100 people and led multiple transactions including J&J, Novartis, Teva, Abbott, Medarex and others. Erez earned his M.B.A., M.Sc. in Microbiology and his B.Sc. from Tel Aviv University.
SHLOMO (Momi) SHALEV
Shlomo Shalev serves as Chairman of the Board of Intercure Ltd, an investor in Regenera and CEO of GFC Capital, an investment company publicly traded in TASE. From 2007 to 2013 Mr. Shalev was leading several companies in Turn Around and growth situations including as chairman of the board of Micronet a company publicly traded in TASE. Prior to that Shlomo served as SVP Investments at Ampal, a diversified holding company. Shlomo was involved in and led a number of transactions including M&A’s and IPO’s. Between 1994 and 1998 Mr. Shalev served as Israel’s Economic Consul to the U.S Northwestern Region. Shlomo has a BA in Economics from Ben Gurion University and MBA from University of SF, CA.
Mr. Shimon joined NovellusDx on 2016. Prior to that he worked for PWC and held the position of senior financial auditor.
Yaron holds a BA in accounting from the Hebrew University of Jerusalem and M.A in internal audit from Bar-Ilan University.
He is a member of the Israeli CFO Forum and a graduate of the professional program of the Forum.